Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Neoplasms 2Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 25Cyclophosphamide 20Nivolumab 13Doxorubicin 13Carboplatin 10Surveys and Questionnaires 9Paclitaxel 9Exercise 9atezolizumab 8Vincristine 8Rituximab 8Radiotherapy 8Prednisone 8Dexamethasone 8Bevacizumab 8venetoclax 7fludarabine 7Pemetrexed 7Fluorouracil 7Docetaxel 7Blood Specimen Collection 7lenvatinib 6dostarlimab 6cemiplimab 6budigalimab 6Oxaliplatin 6Cisplatin 6durvalumab 5Leucovorin 5Lenalidomide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms × telisotuzumab vedotin × Clear all
NCT03539536 2025-11-05

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

AbbVie

Phase 2 Active not recruiting
270 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
237 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡